TrialGynecologic oncology2018

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.

William P Tew et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.